Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Patients with estrogen receptor (ER)‐positive breast cancer are less likely to achieve a pathological complete response (pCR) with neoadjuvant chemotherapy. Neoadjuvant endocrine therapy may be more appropriate than neoadjuvant chemotherapy in these hormone‐sensitive patients. Most patients with ER‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Nobuaki, Masuda, Norikazu, Morimoto, Takashi, Ueno, Takayuki, Kanbayashi, Chizuko, Kaneko, Koji, Yasojima, Hiroyuki, Saji, Shigehira, Sasano, Hironobu, Morita, Satoshi, Ohno, Shinji, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051169/
https://www.ncbi.nlm.nih.gov/pubmed/29905023
http://dx.doi.org/10.1002/cam4.1600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051169/
https://www.ncbi.nlm.nih.gov/pubmed/29905023
http://dx.doi.org/10.1002/cam4.1600

Ejemplares similares